2-(3-(4-n-butylpiperidine-1-yl)-propyl)-benzooxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-(3-(4-n-butylpiperidine-1-yl)-propyl)-benzooxazole
• 英文别名: 2-[3-(4-Butylpiperidin-1-yl)propyl]-1,3-benzoxazole
• 化学式: C₁₉H₂₈N₂O
• 分子量: 300.444
• InChiKey: WYRYFLFMLZKIHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  29.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Muscarinic agonists
  申请人：——

  公开号：US20020037886A1

  公开（公告）日：2002-03-28

  Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

  提供了用于治疗疾病症状的化合物和方法，在这些疾病症状中，改变胆碱能，尤其是肌磷酸激酶m1、m4或m1和m4双重受体活性对疗效有益。在该方法中，向需要此类治疗的患者施用有效量的化合物。
• MUSCARINIC AGONISTS
  申请人：Andersson A. Carl-Magnus

  公开号：US20070155795A1

  公开（公告）日：2007-07-05

  Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

  本发明提供了用于治疗疾病状态的化合物和方法，其中修改胆碱能，特别是肌动蛋白m1，m4或m1和m4的受体活性对疗效有益。在该方法中，向需要此类治疗的患者施用有效量的化合物。
• US6627645B2
  申请人：——

  公开号：US6627645B2

  公开（公告）日：2003-09-30
• US7238713B2
  申请人：——

  公开号：US7238713B2

  公开（公告）日：2007-07-03
• [EN] MUSCARINIC AGONISTS<br/>[FR] AGONISTES MUSCARINIQUES
  申请人：ACADIA PHARM INC

  公开号：WO2001083472A1

  公开（公告）日：2001-11-08

  Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.